International Stem Cell Corp Receives Important Approvals Towards Creating New Parthenogenetic Stem Cell Lines in the US

March 2011
Biomedical Market Newsletter;3/31/2011, p104
The article reports on the approval given to International Stem Cell Corp. in order to move forward to the next phase of its stem cell banking program. The approval has come from Stem Cell Research Oversight (SCRO) committee in which they are the responsible for reviewing the ethics and compliance of State and Federal regulations and guidelines for studies that involve human stem cells. Simon Craw of the company, says that the approval plus with their technology will lead to a positive research.


Related Articles

  • Intl Stem Cell Corp Appoints MZ Group as its Investor Relations Firm.  // Biomedical Market Newsletter;4/28/2012, Vol. 21, p1 

    The article focuses on management changes made by International Stem Cell Corp. including appointment of MZ Group as its investment advisor and promotion of Simon Craw. Ted Haberfield, Managing Partner of MZ Group North America, states that with the help of its advanced research and development,...

  • Stem Cell Panel Approves Of Collection Program. Hirsh, Lou // San Diego Business Journal;3/28/2011, Vol. 32 Issue 13, p42 

    The article reports on the decision of Stem Research Oversight Committee to approve the next phase of a stem cell collection program of International Stem Cell Corp.

  • Stem cells: US policies on human embryonic stem cells. Hynes, Richard O. // Nature Reviews Molecular Cell Biology;Dec2008, Vol. 9 Issue 12, p993 

    The United States is a federal union with separate state jurisdictions. In part owing to the sometimes heated debate about public support for human embryonic stem-cell (ESC) research, there has been restricted federal support and little central regulation of this research to date. Instead,...

  • Stem-cell lines set for German research.  // Medical Device Daily;3/4/2008, Vol. 12 Issue 43, p8 

    The article reports on the use of International Stem Cell's (ISCO) human parthenogenetic stem cell lines in Germany in studies aimed at creating cell types to treat neural diseases. The study will be headed by Albrecht Mueller of the University of Wuerzburg. ISCO chief executive Kenneth Aldrich...

  • Four firms in plan to develop embryonic stem cell technology.  // Medical Device Daily;4/4/2008, Vol. 12 Issue 66, p6 

    The article reports on a letter of intent signed by BioTime and its Embryome Sciences subsidiary with International Stem Cell Corp. and its subsidiary Lifeline Cell Technology to jointly produce and distribute a variety of research products from human embryonic stem cell technology. According to...

  • Agreements/contracts.  // Medical Device Daily;3/13/2009, Vol. 13 Issue 48, p10 

    The article reports on a collaboration between International Stem Cell and tissue engineers at Cytograft Tissue Engineering to design a custom cell culture medium to cultivate living human vascular grafts. It is noted that the grafts will be used in future human clinical trials. Scientists at...

  • ISCO Scientists to Present Results of Recent Stem Cell Research on Central Nervous System and Liver Diseases at Annual Meeting of American Society of Gene and Cell Therapy.  // Biomedical Market Newsletter;5/17/2011, p565 

    The article focuses on the announcement of International Stem Cell Corp. (ISCO) that doctors Ruslan Semechkin and Nikolay Turovets will present the human parthenogenetic stem cells (HPSC) research at the 14th Annual Meeting of the American Society of Gene and Cell Therapy in Seattle, Washington....

  • The Court of Justice of the European Union Clarifies when Human Embryonic Stem Cells Can Be Patented. Bonadio, Enrico; Rovati, Angelo Maria // European Journal of Risk Regulation;2015, Vol. 6 Issue 2, p293 

    The article discusses the European court case International Stem Cell Corporation v. Comptroller General of Patents, Designs and Trade Marks regarding the embryonic stem cell technologies. The Court of Justice of the European Union (CJEU) made a distinction of the stem cell biotechnologies based...

  • Stem cell research, center need support.  // Crain's Detroit Business;1/18/2010, Vol. 26 Issue 3, p6 

    The article presents the author's opinion on opportunities for Michigan to transform medical research into commercial applications after the removal of restrictions on stem cell research. The author suggests that Michigan lawmakers should lay off trying to do an end run around what voters...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics